| Download a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Sandoz, currently based in Vienna, Austria, is the generics business of
Novartis, and makes up part of Novartis' Consumer Health Division. This report
provides an insight into the company, reviewing its current business structure
and activities.
Prior to Sandoz' re-branding in May 2003, Novartis' generics business had been
made up of 14 separate firms. The re-branding was completed in 2005, with the
exception of Lek, which remains a separate Slovenia-based company for the time
being. The company is one of the largest generic pharmaceuticals businesses in
the world. Sandoz currently employs over 20,000 people in 110 countries. It
operates through three business franchises:
- The Pharmaceuticals Business produces finished dosage forms, which
are sold to pharmacies, hospitals and other healthcare outlets;
- The Biopharmaceutical Business draws on the company's experience with
biotechnology, and is expanding to meet demand;
- The Industrial Business manufactures active pharmaceutical
ingredients and their intermediates for internal requirements and industrial
partners.
This report provides information on the company's active product lines and
ANDA approvals, along with a review of major developments, such as M&A
activity, strategic alliances and litigation. The company's most recent
quarterly and annual financial results are illustrated with comparative
figures, charts and a detailed review of the data which allows you to track
the company's progress.
TABLE OF CONTENTS
- EXECUTIVE SUMMARY
- INTRODUCTION
- PRODUCTS3
- Sandoz ANDA Approvals, 2002-06
- Geneva Pharmaceuticals ANDA Approvals, 2002-03
- Lek ANDA Approvals, 2002-03
- Eon Labs ANDA Approvals, 2002-05
- Recent product approvals - S
- EU positive opinion for Omnitrope
- US zonisamide approval
- US cefprozil approval
- US azithromycin approval
- US leflunomide approval
- US ceftriaxone injection launch announ
- Australian TGA approves Omnitrope
- Recent product approvals - Hex
- Tramadol (Labopharm)
- Fentanyl patch
- Recent product approvals - Eon Labs.
- Recent product approvals - Lek
- Lek's pravastatin launched in Europe
- FINANCIAL RESULTS
- Latest Yearly Results
- Sandoz: 2005 results (US$ millions)
- Latest Quarterly Results
- Sandoz: fourth quarter 2005 results (US$ millions)
- MAJOR DEVELOPMENTS
- Facilities
- Lek opens new facility in Slovenia
- Mergers, acquisitions and agreements
- Momenta and Sandoz develop generic M-enoxaparin
- Sandoz completes purchase of Hexal and Eon Labs
- Novartis India plans to transfer facility to Sandoz
- Sabex
- Durascan
- Amifarma
- Lek acquisition
- Litigation
- Pfizer petitions the FDA to recall Teva's and Sandoz' azithromycin
products
- AstraZeneca and Eon Labs in metoprolol patent litigation
- Sandoz files lawsuit against FDA regarding Omnitrope
- Amoxicillin and clavulanate
- CONTACT DETAILS
|
